A conversation with Leesa Gentry, chief clinical officer, RenovoRx
Most clinical trials involve three core parties in their execution: the sponsor, the site, and the CRO. Recently, this approach has maintained dominance, but from time to time, sponsor preferences change their approach and take execution of the trial into their own hands.
Such is the case with RenovoRx and TIGer-PaC, its Phase 3 head-to-head superiority trial for RenovoCath, which delivers chemotherapy intra-arterially instead of standard of care IV administration for those with locally advanced pancreatic cancer.
In this Q&A, RenovoRx Chief Clinical Officer Leesa Gentry explains why they decided to forgo a CRO partner, discusses their in-house expertise, and shares how the decision helped them get closer to patients.